ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

5,5-ジフェニルヒダントイン

Phenytoin

HCID 1775
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
57-41-0
標準SMILES
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
InChIKey
CXOFVDLJLONNDW-UHFFFAOYSA-N
分子式
C15H12N2O2
平均分子量
252.27 g/mol
単同位体質量
252.08987763

概要

Diphenylhydantoin (Phenytoin) can cause cancer and developmental toxicity according to an independent committee of scientific and health experts.

名称と識別子

優先名称
Phenytoin
IUPAC
5,5-diphenylimidazolidine-2,4-dione
現地名
5,5-ジフェニルヒダントイン
英語名
5,5-Diphenylhydantoin
分子式
C15H12N2O2
分子量
252.27

名称と別名

phenytoin5,5-DIPHENYLHYDANTOIN57-41-0Diphenylhydantoin5,5-diphenylimidazolidine-2,4-dionePhenytoineZentropilLepitoinDiphantoinEpaminDihydantoinDilabid
名称をさらに表示
5,5-ジフェニルヒダントインデニルソダントンエプタル1,5-ジヒドロ-5,5-ジフェニル-2H-イミダゾール-2,4(3H)-ジオンジフェントインジラビッドジ-ヒダンヒダンタール4,4-ジフェニル-2,3,4,5-テトラヒドロ-1H-イミダゾール-2,5-ジオンヒダントール5,5-ジフェニル-イミダゾリジン-2,4-ジオン5,5-ジフェニルイミダゾリジン-2,4-ジオンジフェニルヒダントインジフェニルヒドラントインジ-ランレピトインジヒコンアレビアチンゼントロピルbaseDantinalPhenitoinPHENYTOIN BASEPHENYTIONPhentoinPhenhydan
SodantonDihyconDiphenylanFenitoinaFenylepsinHidantalSilantinDenyl

データベース識別子

CAS
57-41-0

物性

構造計算による物性

XLogP
2.5
極性表面積
58.2 Ų
水素結合供与体数
2
水素結合受容体数
2
回転可能結合数
2
重原子数
19
形式電荷
0
複雑度
350

実験および物理化学的性質

Chemical Classes · 2 件

Carcinogens

Pharmaceutical

Drugs · 4 件

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antiepileptic

SpringerMaterials PropertiesCrystal structure
LogP · 3 件

log Kow = 2.47

2.2

2.21

OdorOdorless
Color/Form · 2 件

Needles (alcohol)

White powder

Solubility · 6 件

less than 0.1 mg/mL at 66 °F (NTP, 1992)

Insoluble in cold water

One gram dissolves in about 60 ml alcohol, about 30 ml acetone. Soluble in alkali hydroxides.

Soluble in acetic acid; slightly soluble in ethyl ether, benzene, chloroform

In water, 32 mg/L at 22 °C

7.11e-02 g/L

Human Drugs · 5 件

Breast Feeding; Lactation; Milk, Human; Anticonvulsants

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 138 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

H402: Harmful to aquatic life [Hazardous to the aquatic environment, acute hazard]

P273, and P501 (click each P-code to see the statement)

危険有害性情報

Regulatory Information · 4 件

Hazard Traits - Carcinogenicity; Developmental Toxicity

REACH registered substance: Phenytoin (EC: 200-328-6)

Phenytoin: Does not have an individual approval but may be used under an appropriate group standard

The New Jersey Worker and Community Right to Know Act requires public and private employers to provide information about hazardous substances at their workplaces. (N.J.S.A. 34:5A-1 et. seq.)

Other Safety InformationIMAP assessments - 2,4-Imidazolidinedione, 5,5-diphenyl-: Human health tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Health Hazards · 1 件

SYMPTOMS: Symptoms of exposure to this compound include ataxia, nystagmus, fever, agranulocytosis, lupus erythematosus, epidermal necrolysis, pseudolymphoma, slurred speech, mental confusion, dizziness, insomnia, transient nervousness, headache, dyskinesias, chorea, dystonia, asterixis, polyneuropathy, nausea, vomiting, constipation, rash (scarlatiniform or morbilliform), dermatitis (bullous, exfoliative or purpuric), thrombocytopenia, leukopenia, granulocytopenia, pancytopenia with or without bone marrow suppression, macrocytosis, megaloblastic anemia, coarsening of the facial features, gingival hyperplasia, toxic hepatitis, respiratory depression, Stevens-Johnson syndrome, coma and death. Other symptoms include central nervous system effects such as depression and motor restlessness, allergic reactions, gastric distress, hirsutism and blood dyscrasias. Exposure can cause liver damage, kidney damage, adenopathy, aplastic anemia, pulmonary changes, lymph gland enlargement, cardiac irregularities, peripheral nerve damage, tremor, drug psychosis, rigidity and convulsions. Exposure can also cause motor twitchings, decreased coordination, enlargement of the lips, hypertrichosis, Peyronie's Disease, periarteritis nodosa, immunoglobulin abnormalities, dysarthria, hyperreflexia, lethargy, hypertension and circulatory depression. It may cause tenderness of the gums, rickets, reduced bone density, osteomalacia, polyarthropathy, hyperglycemia, erythema multiforme, hypotension, blurred vision, unsteady gait, facial changes, thickening of the skull, thickening of the heel pad, eosinophilia, hemolytic anemia, myasthenia gravis, acquired hemophilia, leukemia, pulmonary function loss, decreased sexual potency and fertility, and cholestasis. It may also cause lymphadenopathy, lymphoma including Hodgkin's disease, hallucinations, excitation, cardiac arrhythmias, cerebellar-vestibular effects, behavioral changes, increased frequency of seizures, gastrointestinal symptoms, vertigo, mydriasis, hyperactivity, silliness, dullness, drowsiness, anorexia, inhibition of release of anti-diuretic hormone, glycosuria, hepatic necrosis, neutropenia and red-cell aplasia. Exposure may lead to blood changes, tumors of the skin and appendages, change in motor activity, degenerative brain changes and jaundice. It may also lead to diplopia, weakness of accommodation and convergence, stuporous mental state, mental disturbance, oscillopsia (very fine periodic dancing of the eyes vertically or horizontally), ophthalmoplegia and conjunctivitis. It can cause the eyes to be temporarily fixed in mid-position and can interfere with the vestibulo-ocular reflex arc.

化学と産業

薬理情報

ATC Code · 4 件

N03AB02

N - Nervous system

QN - Nervous system

N03AB02

Protein BindingPhenytoin is roughly 90% protein bound.
Pharmacodynamics · 1 件

Phenytoin is an anticonvulsant with a narrow therapeutic index. Although the recommended therapeutic range is cited to be between 10-20 mg/L, differences in albumin levels, genetics, comorbidities, and body composition can make achieving an ideal phenytoin dose challenging. For example, studies have confirmed that phenytoin metabolism is impacted by CYP2C9 genotype polymorphisms and possibly by CYP2C19 genotype polymorphisms (the latter has not been as extensively studied). It is worth nothing that although phenytoin is highly protein bound, only the fraction unbound is able to exert a pharmacological effect. Therefore, factors that reduce or increase the percentage of protein bound phenytoin (for example: concomitant administration of drugs that can cause displacement from protein binding sites) can have a marked impact on phenytoin therapy.

Mechanism of Action · 6 件

Although phenytoin first appeared in the literature in 1946, it has taken decades for the mechanism of action to be more specifically elucidated. Although several scientists were convinced that phenytoin altered sodium permeability, it wasn’t until the 1980’s that this phenomenon was linked to voltage-gated sodium channels. Phenytoin is often described as a non-specific sodium channel blocker and targets almost all voltage-gated sodium channel subtypes. More specifically, phenytoin prevents seizures by inhibiting the positive feedback loop that results in neuronal propagation of high frequency action potentials.

The mechanism of action is not completely known, but it is thought to involve stabilization of neuronal membranes at the cell body, axon, and synapse and limitation of the spread of neuronal or seizure activity. In neurons, phenytoin decreases sodium and calcium ion influx by prolonging channel inactivation time during generation of nerve impulses. Phenytoin blocks the voltage-dependant sodium channels of neurons and inhibits the calcium flux across neuronal membranes, thus helping to stabilize neurons. It also decreases synaptic transmission, and decreases post-tetanic potentiation at the synapse. Phenytoin enhances the sodium ATPase activity of neurons and/or glial cells. It also influences second messenger systems by inhibiting calcium-calmodulin protein phosphorylation and possibly altering cyclic nucleotide production or metabolism.

関連反応

48 件
反応記録を作成
HRID 28065 の反応式
HRID 28065生成物として
HRID 52593 の反応式
HRID 52593反応物として
HRID 137011 の反応式
HRID 137011反応物として
HRID 138603 の反応式
HRID 138603反応物として
HRID 152800 の反応式
HRID 152800反応物として
HRID 196375 の反応式
HRID 196375反応物として
HRID 223597 の反応式
HRID 223597生成物として
HRID 260209 の反応式
HRID 260209反応物として
前へ1 / 6 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
PubChem CID
1775
DTXSID
DTXSID8020541
ChEMBL
CHEMBL16
ChEBI
CHEBI:8107
UNII
6158TKW0C5
EC Number
200-328-6
Nikkaji
J2.325F

Pharmaceuticals

Antiseizure medicines

DecompositionWhen heated to decomposition it emits very toxic fumes of /nitrogen oxides/.
Melting Point · 3 件

563 to 568 °F (NTP, 1992)

295-298 °C

286 °C

Physical Description · 2 件

Phenytoin appears as fine white or almost white crystalline powder. Odorless or almost odorless. Tasteless. (NTP, 1992)

Solid

Stability/Shelf Life · 2 件

Sensitive to light

A slight yellowing of the solution will not affect its potency. After being refrigerated, solution may form a precipitate which usually dissolves after being warmed to room temperature; however, do not use if the solution is not clear. /Phenytoin Sodium Injection USP/

物理化学的性質

融点
293 · 293-295 °C (lit.)
沸点
395.45 °C · 395.45°C (rough estimate)
比重(密度)
1.1562 · 1.1562 (rough estimate)
屈折率
1.5906 · 1.5906 (estimate)
闪点
11 °C · 11 °C
貯蔵温度
2 · 2-8°C
溶解性
DMSO:可溶
酸解離定数(Pka)
8.43 · pKa 8.43(H2O,t =25,I=0.025) (Uncertain)
外見
粉
色
白~ほぼ白
由来生物
rabbit
水溶解度
0.01 g/100 · <0.01 g/100 mL で 19 ºC
Merck
14 · 14,7322
BRN
384532 · 384532
Henry's Law Constant
9.7 · 9.7×105 mol/(m3Pa) at 25℃, HSDB (2015)
安定性
安定。可燃性。強酸化剤、強塩基とは相容れない。
InChI
1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)
InChIKey
CXOFVDLJLONNDW-UHFFFAOYSA-N
SMILES
O=C1NC(=O)C(N1)(c2ccccc2)c3ccccc3
CAS データベース
57 · 57-41-0(CAS DataBase Reference)
NISTの化学物質情報
5 · 5,5-Diphenylhydantoin(57-41-0)
EPAの化学物質情報
Phenytoin (57-41-0)

化学的性質

化学的特性white crystals or powder

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl phenytoin approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Reactive GroupAmides and Imides
Special Reports · 5 件

A REVIEW OF THE REPORTED RISKS OF PHENYTOIN DURING PREGNANCY.[ALBENGRES E, TILLEMENT JP; PHENYTOIN IN PREGNANCY: A REVIEW OF THE REPORTED RISKS; BIOL RES PREGNANCY PERINATOL 4(2) 71 (1983)]

DHHS/NTP; Toxicology & Carcinogenesis Studies of 5,5-Diphenylhydantoin in F344/N Rats and B6C3F1 Mice (Feed Studies) Technical Report Series No. 404 (1993) NIH Publication No. 94-2859

Strasnick B, Jacobson JT; J Am Acad Audiol 6 (1): 28-38 (1995). Teratogenic hearing loss /is reviewed/.

Wasfi FA, et al; Med Sci Res 23 (8): 551-3 (1995). Teratogenic effects of phenytoin in the rat: an in vivo and an in vitro study.

For more Special Reports (Complete) data for PHENYTOIN (8 total), please visit the HSDB record page.

Reactivity Profile · 1 件

PHENYTOIN is an amide. Amides/imides react with azo and diazo compounds to generate toxic gases. Flammable gases are formed by the reaction of organic amides/imides with strong reducing agents. Amides are very weak bases (weaker than water). Imides are less basic yet and in fact react with strong bases to form salts. That is, they can react as acids. Mixing amides with dehydrating agents such as P2O5 or SOCl2 generates the corresponding nitrile. The combustion of these compounds generates mixed oxides of nitrogen (NOx). This chemical is incompatible with strong oxidizers and strong bases. (NTP, 1992)

Air and Water ReactionsInsoluble in water.
Hazard Classes and Categories · 4 件

Acute Tox. 4 (100%)

Acute toxicity (Oral) - Category 4

Hazardous to the aquatic environment (Acute) - Category 3

Carcinogens, Mutagens, Teratogens

Shipment Methods and Regulations · 2 件

PRECAUTIONS FOR "CARCINOGENS": Procurement ... of unduly large amt ... should be avoided. To avoid spilling, carcinogens should be transported in securely sealed glass bottles or ampoules, which should themselves be placed inside strong screw-cap or snap-top container that will not open when dropped & will resist attack from the carcinogen. Both bottle & the outside container should be appropriately labelled. ... National post offices, railway companies, road haulage companies & airlines have regulations governing transport of hazardous materials. These authorities should be consulted before ... material is shipped. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": When no regulations exist, the following procedure must be adopted. The carcinogen should be enclosed in a securely sealed, watertight container (primary container), which should be enclosed in a second, unbreakable, leakproof container that will withstand chem attack from the carcinogen (secondary container). The space between primary & secondary container should be filled with absorbent material, which would withstand chem attack from the carcinogen & is sufficient to absorb the entire contents of the primary container in the event of breakage or leakage. Each secondary container should then be enclosed in a strong outer box. The space between the secondary container & the outer box should be filled with an appropriate quantity of shock-absorbent material. Sender should use fastest & most secure form of transport & notify recipient of its departure. If parcel is not received when expected, carrier should be informed so that immediate effort can be made to find it. Traffic schedules should be consulted to avoid ... arrival on weekend or holiday ... /Chemical Carcinogens/

安全と保護具

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)
First Aid · 1 件

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Storage Conditions · 5 件

PRECAUTIONS FOR "CARCINOGENS": Storage site should be as close as practical to lab in which carcinogens are to be used, so that only small quantities required for ... expt need to be carried. Carcinogens should be kept in only one section of cupboard, an explosion-proof refrigerator or freezer (depending on chemicophysical properties ...) that bears appropriate label. An inventory ... should be kept, showing quantity of carcinogen & date it was acquired ... Facilities for dispensing ... should be contiguous to storage area. /Chemical Carcinogens/

Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Protect from freezing. /Phenytoin Oral Suspension USP/

Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. /Phenytoin Tablets (Chewable) USP/

Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. /Extended Phenytoin Sodium Capsules USP/

For more Storage Conditions (Complete) data for PHENYTOIN (6 total), please visit the HSDB record page.

Cleanup Methods · 1 件

PRECAUTIONS FOR "CARCINOGENS": A high-efficiency particulate arrestor (HEPA) or charcoal filters can be used to minimize amt of carcinogen in exhausted air ventilated safety cabinets, lab hoods, glove boxes or animal rooms ... Filter housing that is designed so that used filters can be transferred into plastic bag without contaminating maintenance staff is avail commercially. Filters should be placed in plastic bags immediately after removal ... The plastic bag should be sealed immediately ... The sealed bag should be labelled properly ... Waste liquids ... should be placed or collected in proper containers for disposal. The lid should be secured & the bottles properly labelled. Once filled, bottles should be placed in plastic bag, so that outer surface ... is not contaminated ... The plastic bag should also be sealed & labelled. ... Broken glassware ... should be decontaminated by solvent extraction, by chemical destruction, or in specially designed incinerators. /Chemical Carcinogens/

Nonfire Spill Response · 1 件

SMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with 60-70% ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with 60-70% ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with 60-70% ethanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Disposal Methods · 5 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

PRECAUTIONS FOR "CARCINOGENS": There is no universal method of disposal that has been proved satisfactory for all carcinogenic compounds & specific methods of chem destruction ... published have not been tested on all kinds of carcinogen-containing waste. ... summary of avail methods & recommendations ... /given/ must be treated as guide only. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": ... Incineration may be only feasible method for disposal of contaminated laboratory waste from biological expt. However, not all incinerators are suitable for this purpose. The most efficient type ... is probably the gas-fired type, in which a first-stage combustion with a less than stoichiometric air:fuel ratio is followed by a second stage with excess air. Some ... are designed to accept ... aqueous & organic-solvent solutions, otherwise it is necessary ... to absorb soln onto suitable combustible material, such as sawdust. Alternatively, chem destruction may be used, esp when small quantities ... are to be destroyed in laboratory. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": HEPA (high-efficiency particulate arrestor) filters ... can be disposed of by incineration. For spent charcoal filters, the adsorbed material can be stripped off at high temp & carcinogenic wastes generated by this treatment conducted to & burned in an incinerator. ... LIQUID WASTE: ... Disposal should be carried out by incineration at temp that ... ensure complete combustion. SOLID WASTE: Carcasses of lab animals, cage litter & misc solid wastes ... should be disposed of by incineration at temp high enough to ensure destruction of chem carcinogens or their metabolites. /Chemical Carcinogens/

For more Disposal Methods (Complete) data for PHENYTOIN (6 total), please visit the HSDB record page.

Preventive Measures · 5 件

PRECAUTIONS FOR "CARCINOGENS": Smoking, drinking, eating, storage of food or of food & beverage containers or utensils, & the application of cosmetics should be prohibited in any laboratory. All personnel should remove gloves, if worn, after completion of procedures in which carcinogens have been used. They should ... wash ... hands, preferably using dispensers of liq detergent, & rinse ... thoroughly. Consideration should be given to appropriate methods for cleaning the skin, depending on nature of the contaminant. No standard procedure can be recommended, but the use of organic solvents should be avoided. Safety pipettes should be used for all pipetting. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": In animal laboratory, personnel should remove their outdoor clothes & wear protective suits (preferably disposable, one-piece & close-fitting at ankles & wrists), gloves, hair covering & overshoes. ... Clothing should be changed daily but ... discarded immediately if obvious contamination occurs ... /also,/ workers should shower immediately. In chemical laboratory, gloves & gowns should always be worn ... however, gloves should not be assumed to provide full protection. Carefully fitted masks or respirators may be necessary when working with particulates or gases, & disposable plastic aprons might provide addnl protection. If gowns are of distinctive color, this is a reminder that they should not be worn outside of lab. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": ... Operations connected with synth & purification ... should be carried out under well-ventilated hood. Analytical procedures ... should be carried out with care & vapors evolved during ... procedures should be removed. ... Expert advice should be obtained before existing fume cupboards are used ... & when new fume cupboards are installed. It is desirable that there be means for decreasing the rate of air extraction, so that carcinogenic powders can be handled without ... powder being blown around the hood. Glove boxes should be kept under negative air pressure. Air changes should be adequate, so that concn of vapors of volatile carcinogens will not occur. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": Vertical laminar-flow biological safety cabinets may be used for containment of in vitro procedures ... provided that the exhaust air flow is sufficient to provide an inward air flow at the face opening of the cabinet, & contaminated air plenums that are under positive pressure are leak-tight. Horizontal laminar-flow hoods or safety cabinets, where filtered air is blown across the working area towards the operator, should never be used ... Each cabinet or fume cupboard to be used ... should be tested before work is begun (eg, with fume bomb) & label fixed to it, giving date of test & avg air-flow measured. This test should be repeated periodically & after any structural changes. /Chemical Carcinogens/

For more Preventive Measures (Complete) data for PHENYTOIN (9 total), please visit the HSDB record page.

Isolation and EvacuationExcerpt from ERG Guide 154 [Substances - Toxic and/or Corrosive (Non-Combustible)]:
Personal Protective Equipment (PPE) · 2 件

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with a combination filter cartridge, i.e. organic vapor/acid gas/HEPA (specific for organic vapors, HCl, acid gas, SO2 and a high efficiency particulate filter). (NTP, 1992)

PRECAUTIONS FOR "CARCINOGENS": ... Dispensers of liq detergent /should be available./ ... Safety pipettes should be used for all pipetting. ... In animal laboratory, personnel should ... wear protective suits (preferably disposable, one-piece & close-fitting at ankles & wrists), gloves, hair covering & overshoes. ... In chemical laboratory, gloves & gowns should always be worn ... however, gloves should not be assumed to provide full protection. Carefully fitted masks or respirators may be necessary when working with particulates or gases, & disposable plastic aprons might provide addnl protection. ... Gowns ... /should be/ of distinctive color, this is a reminder that they are not to be worn outside the laboratory. /Chemical Carcinogens/

毒性情報

Treatment · 1 件

Treatment is nonspecific since there is no known antidote. The adequacy of the respiratory and circulatory systems should be carefully observed and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe intoxication in pediatric patients. (L1712)

Interactions · 5 件

Risk of hepatotoxicity from a single toxic dose or prolonged use of acetaminophen may be increased and therapeutic efficacy may be decreased in patients regularly taking other hepatic enzyme-inducing agents such as phenytoin.

Concurrent use of alcohol or CNS depression-producing medications with hydantoin anticonvulsants may enhance CNS depression. Chronic use of alcohol may decrease serum concentrations and effectiveness of hydantoins; concurrent use of hydantoin anticonvulsants with acute alcohol intake may increase serum hydantoin concentrations. /Hydantoin anticonvulsants/

Concurrent use of amiodarone with phenytoin and possibly with other hydantoin anticonvulsants may increase plasma concentrations of the hydantoin, resulting in increased effects and/or toxicity.

Concurrent use with coumarin- or indandione-derivative anticoagulants, chloramphenicol, cimetidine, disulfiram, influenza virus vaccine, isoniazid, methylphenidate, phenylbutazone, ranitidine, salicylates, sulfonamide, trazodone, or trimethoprim may increase serum concentrations of phenytoin because of decreased metabolism, thereby increasing the effects and/or toxicity phenytoin. Dosage adjustments of the anticonvulsant may be necessary.

For more Interactions (Complete) data for PHENYTOIN (50 total), please visit the HSDB record page.

Health EffectsMay cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Hepatotoxicity · 1 件

Prospective studies indicate that a fairly high proportion of patients taking phenytoin have transient serum aminotransferase elevations. These elevations are usually benign, not associated with liver histological abnormalities and usually resolve even with drug continuation. In addition, a higher proportion of patients have mild-to-moderate elevations in gammaglutamyl transpeptidase (GGT) levels, which is indicative of hepatic enzyme induction rather than liver injury. Marked aminotransferase elevations (>3 fold elevated) occur rarely.

Environmental Fate · 3 件

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 520(SRC), determined from a log Kow of 2.47(2) and a regression-derived equation(3), indicates that phenytoin is expected to have moderate mobility in soil(SRC). Volatilization of phenytoin from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.02X10-11 atm-cu m/mole(SRC), using a fragment constant estimation method(4). Phenytoin is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.2X10-10 mm Hg(SRC), determined from a fragment constant method(5). Biodegradation data were not available(SRC, 2007).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 520(SRC), determined from a log Kow of 2.47(2) and a regression-derived equation(3), indicates that phenytoin is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 1.02X10-11 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 16(SRC), from its log Kow(2) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2007).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), phenytoin, which has an estimated vapor pressure of 1.2X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase phenytoin may be removed from the air by wet or dry deposition(SRC). Phenytoin does not absorb at wavelengths >290 nm(3) and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Adverse EffectsAdverse effects potentially include the following:
Exposure RoutesIntravenous, Oral, Intramuscular. Bioavailability 70-100% oral, 24.4% for rectal and intravenous administration. Rapid rate of absorption with peak blood concentration expected in 1&frac12; to 3 hours.
Milk ConcentrationsPhenytoin appears to be distributed into milk in small amounts.
Toxicity Summary · 3 件

IDENTIFICATION: Phenytoin is an antiepileptic drug. Phenytoin is a white solid crystalline substance or a solid powder. It is odorless, and tasteless. It is soluble in water, alcohol and practically insoluble in chloroform, in ether and in methylene chloride. HUMAN EXPOSURE: Main risks and target organs: The intoxication usually manifests as mild central nervous system effects. More severe manifestations may be seen following massive overdose but fatalities are extremely rare. Summary of clinical effects: Onset of symptoms including lateral nystagmus, ataxia, and drowsiness occurs within 1 to 2 hours after ingestion and may persist for about 4 to 5 days. In more severe cases, horizontal nystagmus, coarse tremor and inability to walk may be observed. In very severe poisoning, conciousness is impaired but coma is rarely observed. Contraindications: Acute intermittent porphyria, hypersensitivity. Intravenous injection in patients with sino-atrial cardiac block, second- or third degree atrio-ventricular block, sinus bradycardia and Adam-Stokes syndrome. Caution is indicated in patients with uremia, hypoalbuminemia, liver function disorders and viral hepatitis. Routes of exposure: Oral: Most common route. Parenteral: Intravenously in status epilepticus. Absorption by route of exposure: Phenytoin is slowly, but almost completely absorbed from the gastro-intestinal tract; the rate of absorption is variable and its bioavailability can differ markedly with different pharmaceutical formulations. Large doses are more slowly absorbed. In severe oral poisoning, gastro-intestinal absorption may continue up to 60 hours. Administration of 100 mg orally to normal volunteers produced two peaks at 2.5 to 3.5 and 10 to 12 hours. Distribution by route of exposure: Phenytoin is widely distributed throughout the body and is extensively (87 to 93%) bound to protein. Plasma binding is almost exclusively to albumin; in individuals with normal plasma albumin concentration and in absence of displacing agents, phenytoin is about 90% plasma bound. Biological half-life by route of exposure: Following oral administration of therapeutic doses, phenytoin has a very variable, dose-dependent half-life. The range for a therapeutic dose is from 8 to 60 hours with an average of from 20 to 30 hours. In overdose in adults the range is from 24 to 230 hours. Metabolism: Phenytoin is extensively metabolizd in the liver to 5-(4-hydroxyphenyl)-5 phenyl-hydantoin, which is inactive. This para hydroxylation of phenytoin is carried out by cytochrome P450 2C9. This enzyme also hydroxylates tolbutamide, and warfarin. This explains the interaction with these substances. The p-hydroxylated phenytoin is in turn conjugated to its glucuronide. Phenytoin hydroxylation is capacity limited because of the saturable enzyme systems in the liver. At therapeutic doses, metabolism is nonlinear (first order kinetics), while at toxic doses the metabolism is linear (zero order kinetics). The p-hydroxylated phenytoin can be oxidized to 3,4- dihydroxyphenyl-phenylhydantoin, the catechol metabolite of phenytoin, and further to the 3-O-methylated catechol metabolite of phenytoin. These metabolites of phenytoin are of possible toxicological interest. Phenytoin is more rapidly metabolised in children. The rate of metabolizm appears to be subject to genetic polymorphism. Phenytoin undergoes entero-hepatic recycling. Elimination by route of exposure: Phenytoin is mainly excreted in the urine as its hydroxylated metabolite (23 to 70%), either free or in conjugated form (5%). About 4% is excreted unchanged, in the urine and 5% in the feces. Small amounts are excreted in the milk. Mode of action: Toxicodynamics: Phenytoin is eliminated mainly through para-hydroxylation by a cytochrome P450 system. The metabolic pathway is subject to saturable kinetics in overdose, allowing accumulation of free phenytoin. Even at therapeutic doses, accumulation of free phenytoin is possible in: hypoalbuminemia, chronic renal failure, hepatic dysfunction, hereditary insufficient para-hydroxylation, and inhibition of phenytoin metabolism by other drugs. Pharmacodynamics: Phenytoin binds to specific site on voltage- dependent sodium channels and is thought to exert its anticonvulsant effect by suppressing the sustained repetitive firing of neurons by inhibiting sodium flux through these voltage dependent channels. Phenytoin stabilizes membranes, protecting the sodium pump in the brain and in the heart. It limits the development of maximal convulsive activity and reduces the spread of convulsive activity from a discharging focus without influencing the focus itself. Phenytoin has antiarrhythmic properties similar to those of quinidine or procainamide. Although phenytoin has minimal effect on the electrical excitability of cardiac muscle, it decreases the force of contraction, depresses pacemaker action and improves atrioventricular conduction. It also prolongs the effective refractory period relative to the action potential duration. Carcinogenicity: Malignancies, including neuroblastoma, in children whose mothers were on phenytoin during pregnancy have been reported. Teratogenicity: Phenytoin is classed as a teratogen risk factor D (Positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk). The epileptic pregnant woman taking phenytoin, either alone or in combination with other anticonvulsants, has a two to three times greater risk of delivering a child with congenital defects. It is not known if this increased risk is due to antiepileptic drugs, the disease itself, genetic factors, or a combination of these, although some evidence indicates that drugs are the causative factor. A recognizable pattern of malformations, known as the fetal hydantoin syndrome has been described and includes craniofacial and limb abnormalities, cleft lip, impaired growth, and congenital heart defects. Drugs displacing phenytoin plasma protein binding sites: Azapropazone, diazoxide, heparin, ibuprofen, phenylbutazone, salicylic acid, sulfadimethoxine, sulfafurazole, sulfamethizole, sulfamethoxydiazine, sulfamethoxypyridazine, tolbutamide and valproic acid. Decreased total and unbound plasma phenytoin concentration: caused by increased metabolism: Folic acid, Dexamethasone, Phenobarbital, Diazepam, Rifampicin, Methadone, Nitrofurantoin, Estrogens and progestagens. Increased unbound fraction of phenytoin secondary to reduced: intrinsic metabolism: Anticonvulsants: Valproic acid, Carbamazepine, Sulthiame, Clobazam, Antithrombotics: Coumarin derivatives and Triclodine, Antituberculous drugs: Isoniazid and PAS, H2 antagonists: Cimetidine, Ranitidine and Omeprazole. Non-steroidal anti-inflammatory agents: Azapropazone, Phenylbutazone, Ibuprofen.Antiinfective agents: Metronidazole and Chloramphenicol Antimycotics: Miconazole, Fluconazole. Psychoactive drugs: Fluoxetine, Risperidone . Miscellaneous: Amiodarone, Allopurinol and Disulfiram. Main adverse effects: Anticonvulsant hypersensitivity syndrome is a potentially fatal drug reaction with cutaneous and systemic manifestations. The findings are: fever, dermatological: erythema, papulous rash. In some cases erythroderma and even a lethal epidermal necrolysis has been reported. Lymphadenopathy (70%): lymphoma and depressed immunological function have been reported. Hepatitis: hepatitis may develop with severe liver failure and death. Hematological: leukocytosis with atypical lymphocytes, eosinophilia, and agranulocytosis. Connective tissues: coarsening of facial features, enlargement of the lips, gingival hyperplasia, hypertrichosis, Peyronie's disease. Clinical effects: Acute poisoning: Ingestion: Onset of symptoms and signs, principally involving the central nervous system, occurs within hours of acute overdose. These manifestations of toxicity may last many days and, in general, correlate with serum phenytoin concentrations. The earliest manifestations of toxicity following overdose are nystagmus on lateral gaze, ataxia and drowsiness. With more severe intoxication, vertical nystagmus, dysarthria, progressive ataxia to the point of inability to walk, hyperreflexia and impaired level of consciousness are observed. Coma and/or respiratory depression is rarely observed and should prompt consideration of an alternative diagnosis. Paradoxical seizures have been reported in severe phenytoin intoxication but are extremely rare. Parenteral exposure: Fatalities have been reported following intravenous administration of phenytoin to elderly patients with cardiac arrhythmias. These complications appear more likely when intravenous phenytoin is administered at a rapid rate and have been attributed to the solvent propylene glycol rather than to the phenytoin itself. The risk of hypotension and arrythmia is minimal when intravenous phenytoin is used as an anticonvulsant and administered at the recommended rate. In a series of 164 patients who received intravenous phenytoin loading following presentation with acute convulsions, the incidence of hypotension was approximately 5%, and the incidence of apnea and cardiac arrhythmias was 0%. Course, prognosis, cause of death: Normally the clinical course is one of gradual resolution of the signs and symptoms of intoxication leading to complete recovery. Death is rare after phenytoin overdose. It has been reported in association with administration of intravenous phenytoin for treatment of cardiac arrhythmias in elderly people, and rarely from coma and hypotension following oral overdose in children. Systematic description of clinical effects: Cardiovascular: Intravenous phenytoin has been reported to cause depression of cardiac conduction, ventricular fibrillation and heart block in elderly people treated for cardiac arrhythmias. Intravenous phenytoin is irritant and may cause phlebitis. Neurological: CNS: Nystagmus, ataxia, dysarthria, drowsiness, coarse resting tremor, ankle clonus, brisk deep tendon reflexes. In severe poisoning, the patient becomes obtunded, confused and disoriented. Coma and respiratory depression are unusual. Hepatic: A phenytoin hypersensitivity syndrome occurs and is characterised by hepatitis. Overall mortality rate when liver is involved is between 18% and 40%. The hepatitis is usually anicteric. Icterus indicates a poorer prognosis. Hepatomegaly with or without plenomegaly may be present. The elevated hepatic transaminases, which may be in the thousands of international units, can continue to rise after phenytoin is discontinued. Phenytoin induced chronic hepatitis has been reported. Phenytoin can induce hyperglycemia by inhibiting the release of insulin. However, hypoglycemia has been reported in a patient treated with phenytoin for 19 years who ingested 20 g phenytoin together with 225 mg zopiclone. Dermatological: In the anticonvulsant hypersensitivity syndrome, the cutaneous eruption begins as a patchy macular erythema that evolves into a dusky, pink red, confluent, papular rash that usually is pruritic. The upper trunk, face, and upper extremities are affected first, with later involvement of the lower extremities. In some cases erythroderma ensues. Patients have periorbital and facial edema. Epidermal necrolysis (even lethal) has been reported. Hematological: A number of adverse haematological effects have been reported. These are not observed following acute overdose. The hematological abnormalities reported include leucocytosis with atypical lymphocytes, eosinophilia, leucopenia and agranulocytosis. The marrow toxicity of anticonvulsants, which may be more likely when used in combination (primidone), is recognized. There may be three mechanisms of toxicity. Firstly, primidone and phenytoin both cause folate deficiency and a megaloblastic anemia. Secondly, an immune mechanism with a phenytoin-dependent antigranulocyte antibody may cause leucopenia, which resolves on discontinuing therapy. Finally, phenytoin may cause a direct toxic effect with pancytopenia and agranulocytosis. Subnormal serum folate concentrations were found in patients with chronic epilepsy treated with phenytoin. It was suggested that folate deficiency resulted from accelerated metabolism of folate consequent upon induction of liver enzymes by anticonvulsants. Immunological: It seems likely that an etiological relationship exists between phenytoin treatment and lymphoma. There is evidence of depressed immunological function in patients given phenytoin. Allergic reactions: Anticonvulsant hypersensitivity syndrome is a potentially fatal drug reaction with cutaneous and systemic manifestations to the arene oxide producing anticonvulsants: phenytoin, carbamazepine, and phenobarbital sodium. The features include fever, rash, lympheadenopathy, periorbital or facial edema, hepatitis, hematologic abnormalities, myalgia, arthralgia and pharyngitis. The reaction may be genetically determined. Other: Connective tissues: coarsening of facial features, enlargment of the lips, gingival hyperplasia and hypertrichosis. /Phenytoin/

Signs and SymptomsSymptoms of overdose include coma, difficulty in pronouncing words correctly, involuntary eye movement, lack of muscle coordination, low blood pressure, nausea, sluggishness, slurred speech, tremors, and vomiting.
Ongoing Test Status · 1 件

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=57-41-0]

Effluent Concentrations · 1 件

Phenytoin was detected in 5 treated sewage effluent samples collected from the Espanola sewage treatment plant in New Mexico from August and September 2000 and April 2001 at concentrations of 250 ng/L (ditch) and 300 ng/L (outfall)(1). The estimated amount of phenytoin in untreated wastewater in the United States is 2,700 ng/L(1).

法規制情報

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl phenytoin approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

安全データ

wgk
3
rtecs
MU1050000
ridadr
2811
毒性
LD50 in mice (mg/kg): 92 i.v.; 110 s.c. (Stille, Brunckow)
hs_code
29332100
risk_code
45-61-22-63-40-39/23/24/25-23/24/25-11-20/21/22
化審法
(9)-621
hazard_code
T,Xn,F
safety_code
53-45-36/37-16-7
hazard_class
6.1(b)
packing_group
II
自然発火温度
550 °C
環境リスク評価
フェニトイン(57-41-0)
Hazard Classifications
Acute Tox. 4 OralCarc. 2Repr. 1B
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
有毒物質データの
57-41-0(Hazardous Substances Data)
危険度評価(NFPA 704基準/消防庁データ)
人的[青]=2

毒性と防護

毒性LD50 2500 mg/kg(ラット,経口).

Phenytoin may act to normalize influx of sodium and calcium to cardiac Purkinje fibers. Abnormal ventricular automaticity and membrane responsiveness are decreased. Also, phenytoin shortens the refractory period, and therefore shortens the QT interval and the duration of the action potential.

Exact mechanism is unknown. Phenytoin may act in the CNS to decrease synaptic transmission or to decrease summation of temporal stimulation leading to neuronal discharge (antikindling). Phenytoin raises the threshold of facial pain and shortens the duration of attacks by diminishing self-maintenance of excitation and repetitive firing.

Phenytoin's mechanisms of action as a muscle relaxant is thought to be similar to its anticonvulsant action. In movement disorders, the membrane stabilizing effect reduces abnormal sustained repetitive firing and potentiation of nerve and muscle cells.

A number of studies suggest that keratinocyte growth factor (KGF) plays a major part in reepithelialization after injury, via binding to the specific KGF receptor (KGFR). Several pharmacological agents, including the anti-epileptic drug phenytoin (PHT), have been widely used clinically to promote wound healing. Although the mechanism of action of PHT in this process is still not well understood, it is possible that the activity of PHT in wound healing is mediated via KGF and the KGFR. In the present study, using the enzyme-linked immunosorbant assay and flow cytometry we have shown that PHT increases KGF secretion and KGFR expression by more than 150% in gingival fibroblasts and epithelial cells, respectively. Moreover, semi-quantitative reverse transcriptase-polymerase chain reaction analysis showed that PHT also markedly increased both KGF and KGFR gene transcription by these cells.

Biological Half-Life · 3 件

Oral administration: The half-life of phenytoin ranges from 7 to 42 hours, and is 22 hours on average. Intravenous administration: The half-life of phenytoin ranges from 10-15 hours.

Following oral administration, the plasma half-life of phenytoin averages about 22 hours, although the half-life has ranged from 7-42 hours in individual patients. The plasma half-life of phenytoin in humans following IV administration ranges from 10-15 hours.

Because phenytoin exhibits saturable, zero-order, or dose-dependent pharmacokinetics, the apparent half-life of phenytoin changes with dose and serum concentrations. this is due to the saturation of the enzyme system responsible for metabolizing phenytoin, which occurs at therapeutic concentrations of the drug. Thus, a constant amount of drug is metabolized (capacity-limited metabolism), and small increases in dose may cause disproportionately large increases in serum concentrations and apparent half-life, possibly causing unexpected toxicity.

Metabolism/Metabolites · 6 件

Phenytoin is extensively metabolized and is first transformed into a reactive _arene oxide intermediate_. It is thought that this reactive intermediate is responsible for many undesirable phenytoin adverse effects such as hepatotoxicity, SJS/TEN, and other idiosyncratic reactions. The _arene oxide_ is metabolized to either a _hydroxyphenytoin_ or _phenytoin dihydrodiol_ metabolite, although the former accounts for about 90% of phenytoin metabolism. Interestingly, two stereoisomers of the _hydroxyphenytoin_ metabolite are formed by CYP2C9 and CYP2C19: _(R)-p-HPPH_ and _(S)-p-HPPH_. When CYP2C19 catalyzes the reaction, the ratio of stereoisomers is roughly 1:1, whereas when CYP2C9 catalyzes the reaction, the ratio heavily favours the "S" stereoisomer. Since the metabolism of phenytoin is in part influenced by genetic polymorphisms of CYP2C9 and CYP2C19, this ratio can be utilized to identify different genomic variants of the enzymes. EPHX1, CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 are responsible for producing the _phenytoin dihydrodiol_ metabolite. _Hydroxyphenytoin_ can be metabolized by CYP2C19, CYP3A5, CYP2C9, CYP3A4, CYP3A7, CYP2B6 and CYP2D6 to a _phenytoin catechol_ metabolite or undergo glucuronidation by UGT1A6, UGT1A9, UGT1A1, and UGT1A4 to a _glucuronide metabolite_ that can be eliminated in the urine. On the other hand, the _phenytoin dihydrodiol_ entity is only transformed to the _catechol_ metabolite. The _catechol metabolite_ can undergo methylation by COMT and be subsequently eliminated in the urine, or can spontaneously oxidize to a _phenytoin quinone_ (NQO1 can transform the quinone back to the catechol metabolite). Of note, although CYP2C18 is poorly expressed in the liver, the enzyme is active in the skin and is involved in the primary and secondary hydroxylation of phenytoin. This CYP2C18 mediated bioactivation may be linked to the manifestation of adverse cutaneous drug reactions associated with phenytoin.

The major route of metabolism of phenytoin is oxidation by the liver to the inactive metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH). Because this metabolism is a saturable process, small increases in dosage may produce substantial increases in plasma phenytoin concentrations...

The rate of hepatic biotransformation is increased in younger children, in pregnant women, in women during menses, and in patients with acute trauma; rate decreases with advancing age. The major inactive metabolite of phenytoin is 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH). Phenytoin may be metabolized slowly in a small number of individuals due to genetic predisposition, which may cause limited enzyme availability and lack of induction.

... Oxidative metabolism of 1 of geminal phenyl rings of diphenylhydantoin ... 5-meta-hydroxyphenyl-(l) and 5-para-hydroxyphenyl-5-phenylhydantoin were detected in urine of man (approx ratio 1:12) ...

Phenytoin has known human metabolites that include 5-(3,4-dihydroxycyclohexa-1,5-dien-1-yl)-5-phenylimidazolidine-2,4-dione, 3'-HPPH, 4-Hydroxyphenytoin, and (2S,3S,4S,5R)-6-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)-3,4,5-trihydroxyoxane-2-carboxylic acid.

Primarily hepatic. The majority of the dose (up to 90%) is metabolized to 5-(4'-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). This metabolite undergoes further glucuronidation and is excreted into the urine. CYP2C19 and CYP2C9 catalyze the aforementioned reaction. Route of Elimination: Most of the drug is excreted in the bile as inactive metabolites which are then reabsorbed from the intestinal tract and excreted in the urine. Urinary excretion of phenytoin and its metabolites occurs partly with glomerular filtration but, more importantly, by tubular secretion. Half Life: 22 hours (range of 7 to 42 hours)

FDA Pharmacological Classification · 6 件

6158TKW0C5

PHENYTOIN

Established Pharmacologic Class [EPC] - Anti-epileptic Agent

Physiologic Effects [PE] - Decreased Central Nervous System Disorganized Electrical Activity

Mechanisms of Action [MoA] - Cytochrome P450 1A2 Inducers

Mechanisms of Action [MoA] - Cytochrome P450 2B6 Inducers

MeSH Pharmacological Classification · 3 件

Drugs used to prevent SEIZURES or reduce their severity.

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.

Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP1A2.

Absorption, Distribution and Excretion · 6 件

Given its narrow therapeutic index, therapeutic drug monitoring is recommended to help guide dosing. Phenytoin is completely absorbed. Peak plasma concentration is attained approximately 1.5-3 hours, and 4-12 hours after administration of the immediate release formulation and the extended release formulation, respectively. It should be noted that absorption can be markedly prolonged in situations of acute ingestion.

The majority of phenytoin is excreted as inactive metabolites in the bile. An estimated 1-5% of phenytoin is eliminated unchanged in the urine.

The volume of distribution of phenytoin is reported to be approximately 0.75 L/kg.

The clearance of phenytoin is non-linear. At lower serum concentrations (less than 10 mg/L), elimination is characterized by first order kinetics. As plasma concentrations increase, the kinetics shift gradually towards zero-order, and finally reach zero-order kinetics once the system is saturated.

Studies using Dilantin have shown that phenytoin and its sodium salt are usually completely absorbed from the GI tract. Bioavailability may vary enough among oral phenytoin sodium preparations of different manufacturers to result in toxic serum concentrations or a loss of seizure control (subtherapeutic serum concentrations)...

Absorption of phenytoin is slow and variable among products (poor in neonates) for oral admininstration, immediate for iv administration, and very slow but complete (92%) for intramuscular administration.

Cellular LocationsCytoplasm
Metabolite PathwaysFosphenytoin (Antiarrhythmic) Action Pathway

用途と製造

Uses · 6 件

MEDICATION (VET)

MEDICATION

Antiepileptic drug useful in the treatment of epilepsy.

THERAP CAT: Anticonvulsant; antiepileptic

THERAP CAT (vet): Anticonvulsant

Use (kg; approx.) in Germany (2009): >2500

Consumption PatternsSales in US for 1990: 1,093,250 standard dosage units; sales in US for 1995: 984,527 standard dosage units
Methods of Manufacturing · 2 件

From benzil, urea and NaOH: BILTZ, BER 41, 1391 (1908); 44, 411 (1911) /Phenytoin sodium/

Prepared from benzophenone: H. R. HENZE, US PATENT 2,409,754 (1946 TO Parke Davis).

Formulations/Preparations · 2 件

Oral: Suspension: 125 mg/5 mL Dilantin-125 (with alcohol <0.6%), (Pfizer), Phenytoin Oral Suspension (with <0.6% alcohol), (Actavis), Phenytoin Oral Suspension (with <0.6% alcohol), (Morton Grove), Phenytoin Oral Suspension (with <0.6% alcohol), (UDL), Phenytoin Oral Suspension (with <0.6% alcohol), (Vistapharm), Phenytoin Oral Suspension (with <0.6% alcohol), (Xactdose). Tablets, chewable: 50 mg Dilantin Infatabs, (Pfizer).

DILANTIN

Use ClassificationPharmaceuticals
応用分野 · 7 件

解説5,5-ジフェニルヒダントイン,分解点295~298 ℃.エタノール,アルカリ水溶液に可溶,クロロホルムに微溶.大脳皮質に作用して,抗けいれん,抗てんかん,抗不整脈作用などを示す.注射用にはナトリウム塩が用いられる.森北出版「化学辞典(第2版)

用途薬理研究用。

用途水酸化ナトリウム溶液 [用途(作用)]ナトリウム透過性抑制作用を 示します。

用途ナトリウム透過性抑制作用を 示します。

説明The drug was first approved for the treatment of epilepsy by the Food and Drug Administration in 1953 and marketed by Parke-Davis as Dilantin. Its primary mechanism of action appears to block voltage-sensitive sodium channels in the brain (especially in the motor cortex), producing a delay in electrical recovery in neurons and stabilizing the threshold against hyperexcitability.

使用5,5-Diphenylhydantoin has been used for phenytoin treatment. It has also been used to slow down or prevent mesoendoderm cell migration.

一般的な説明Fine white or almost white crystalline powder. Odorless or almost odorless. Tasteless.

調製方法

純化方法Crystallise the hydantoin from EtOH. [Beilstein 24 III/IV 1748.]

上流・下流製品情報

上流原料

ベンズアルデヒド炭酸ジアンモニウムシアン化カリウムベンゾフェノンBenzeneacetamide, a-amino-a-phenyl-2-アミノ-1,5-ジヒドロ-4H-イミダゾール-4-オンパラバン酸5,5-ジフェニル-2-チオキソイミダゾリジン-4-オンベンゾイン

下流製品

2,4,6-トリフルオロフェノール4,5-dihydroxy-4,5-diphenylimidazolidin-2-one1-Imidazolidineacetic acid, 2,5-dioxo-4,4-diphenyl-, ethyl ester3a,6a-ジフェニル-3a,4,6,6a-テトラヒドロイミダゾ[4,5-d]イミダゾール-2,5(1H,3H)-ジオンクレアチニン1,3-ジブロモ-5,5-ジフェニルヒダントイン

補足説明

定義ChEBI: A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5.

Phenytoin displays its primary signs of toxicity on the nervous and cardiovascular systems. Overdose of oral phenytoin mainly causes neurotoxicity, whereas cardiovascular toxicity is the main side effect of parenteral administration.

Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses. Loss of post-tetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas.